Mission

ICER's mission is to lead innovation in comparative effectiveness research through methods that integrate considerations of clinical benefit and economic value.  Through a unique collaboration with patients, clinicians, manufacturers, insurers and other healthcare stakeholders, ICER develops tools to support patient decisions and medical policy that share the goal of achieving maximum value for every healthcare dollar.

Staff Only

Remember Me
TwitterLinkedinFacebookFeed
Institute for Clinical and Economic Review

At a time of tension between vigorous innovation and increasing costs in health care, health care decision makers require comprehensive evidence of the value of new drugs, devices, procedures, and biologics.  Policy makers and proponents of health care system reform thus routinely argue that simultaneously meeting the goals of sustained innovation, cost control, and improved quality within the health care system will require more explicit appraisal of the clinical effectiveness and comparative value of new and existing interventions. The Institute for Clinical and Economic Review (ICER) was created to fill this evidence gap.

FIRST ANNUAL CER NATIONAL LEADERSHIP AWARDS

 ICER is sponsoring the first annual Comparative Effectiveness Research National Leadership Award.  This award recognizes individuals who have been innovative leaders in advancing the methods and practical applications of comparative effectiveness research in the United States.  

Individuals are eligible for nomination if they have demonstrated a commitment to the rigorous conduct or implementation of comparative effectiveness research aimed at improving the quality and value of health outcomes.  Nominations will be reviewed by ICER and an advisory committee of select members of the comparative effectiveness research community.  More details on the awards. 

Nominations are now being accepted and will close on May 31, 2012.  

  

Cepac_logo.jpg

New England Comparative Effectiveness Public Advisory Council

CEPAC is a regional body whose goal is to provide objective, independent guidance on the application of medical evidence to clinical practice and payer policy decisions across New England. Supported by a federal grant from the Agency for Healthcare Research and Quality (AHRQ), and with backing from a consortium of New England state health policy leaders, CEPAC holds two public meetings a year to consider evidence reviews of medical tests and treatments and provide judgments regarding how the evidence can best be used across New England to improve the quality and value of health care services.  For more information, please visit the CEPAC website.  


ICER, in collaboration with the Alliance for Appropriate and Affordable Healthcare, has launched a web-based patient decision aid to help low-risk prostate cancer patients understand the management options available for the condition.  The website is a community tool that translates ICER's comparative effectiveness research into patient-friendly information.